Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Rhiannon Fahey

Nurse Practitioner, Gerontology Trinity, FL Nurse Practitioner

NPI 1376935692 CMS profile 10627660

9320 State Road 54, Trinity, FL 34655

Open in the dashboard

General payments

$11,410

544 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rhiannon Fahey of Trinity, FL is reported in the CMS Open Payments database as having received $11,410 across 544 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,165 186
2024 General $1,632 68
2023 General $1,619 73
2022 General $2,443 130
2021 General $1,551 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rhiannon Fahey
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Rhiannon Fahey were reported at $4,165. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Rhiannon Fahey Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,551 $133 $44–$396 $132
2022 $2,443 $142 $48–$452 $149
2023 $1,619 $158 $53–$482 $160
2024 $1,632 $171 $55–$533 $164
2025 $4,165 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Janssen Biotech, Inc. $1,214 59 payments
  2. AstraZeneca Pharmaceuticals LP $655 31 payments
  3. Novartis Pharmaceuticals Corporation $642 45 payments
  4. Daiichi Sankyo Inc. $614 24 payments
  5. Incyte Corporation $603 20 payments
  6. Bayer HealthCare Pharmaceuticals Inc. $491 20 payments
  7. Merck Sharp & Dohme Corporation $478 21 payments
  8. AbbVie, Inc. $433 20 payments
  9. Genzyme Corporation $413 20 payments
  10. Astellas Pharma US Inc $333 13 payments
  11. Other $5,533 271 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $11,078 539 payments
  2. Education $332 5 payments
Products named General payments · program years 2021–2025
  1. DARZALEX $480 27 payments
  2. KEYTRUDA $478 21 payments
  3. RYBREVANT $450 15 payments
  4. JAKAFI $427 15 payments
  5. LIBTAYO $413 20 payments
  6. ENHERTU $407 20 payments
  7. Nubeqa $388 13 payments
  8. IMBRUVICA Oncology $382 27 payments
  9. IMBRUVICA Oncology $341 14 payments
  10. CALQUENCE $284 11 payments
  11. Other $9,530 477 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

231

Median for Nurse Practitioner: 389

Drug cost

$319,763

Median for Nurse Practitioner: $21,885

Branded share of claims

32%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imbruvica Ibrutinib Brand 20 $305,064
Eliquis Apixaban Brand 19 $10,942
Anastrozole Generic 42 $1,214
Ondansetron Odt Ondansetron Brand 24 $878
Dexamethasone Generic 19 $456
Mirtazapine Generic 11 $418
Prednisone Generic 44 $361
Prochlorperazine Maleate Generic 14 $307
Ciprofloxacin Hcl Generic 14 $46
Alendronate Sodium Generic 13 $44

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 48 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JAKAFI
  • Incyte Corporation $135
$135 — —
Nubeqa
  • Bayer HealthCare Pharmaceuticals Inc. $125
$125 — —
Lenvima
  • Eisai Inc. $96
$96 — —
VENCLEXTA
  • AbbVie, Inc. $76
$76 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $54
  • Daiichi Sankyo Inc. $15
$70 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 48 with Patron

Records

544 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record